SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications
May 11 2021 - 1:25PM
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or
the “Company”), an original equipment manufacturer of silicon
nitride ceramic for medical and non-medical applications, announced
today the FleX SNTM branded line of its silicon nitride based
products. FleX SN reflects the company’s evolution from producing
monolithic spinal implants, to a wider array of silicon nitride
based technologies for use in biomedical and antipathogenice
applications, such as particulate silicon nitride, polymer
composites, and coatings on other materials.
SINTX’s FleX SN brand of silicon nitride
products are created under a highly flexible R&D model, with
high quality and performance, for use in many biomedical and
antipathogenic applications such as wound care and dressings,
spinal and dental implants, consumer facemasks, and more. Only FleX
SN branded products offer the same formulation of silicon nitride
that has proven its safety in over 40,000 spine fusion surgeries,
and that has been rigorously tested to confirm a wide range of
antiviral, antifungal and antibacterial properties.
Initial products available under the new FleX SN brand
include:
- FleX SN-MC2 (Ultra-dense silicon
nitride ceramic used in FDA cleared medical implants)
- FleX SN-CSC (Features a combined
architecture that can mimic the cortical-cancellous structure of
bone and is used in FDA cleared medical implants )
- FleX SN-PEEK (Combines the unique
bioactivity of silicon nitride with the properties of conventional
PEEK polymer)
- FleX SN-AP (Antipathogenic silicon
nitride powder with targeted effectiveness against viruses such as
SARS-CoV-2 (COVID-19), with proven mammalian cell
compatibility)
The rebranding includes a redesign of the
company’s website, product logos, graphics, communications and
correspondence. Additionally SINTX has submitted a trademark
application for FleX SN which we anticipate will be awarded in the
coming months.
“Since we announced our name change to SINTX
Technologies in 2018, the company has been on a journey to
re-invent itself,” said Dr. Sonny Bal, President and CEO at SINTX
Technologies. “We continue to focus on developing silicon nitride
material properties, product design, and new applications in the
biomedical space. Additionally, we have broadened our market focus
to identify more antipathogenic and industrial applications for
silicon nitride.”
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes silicon nitride for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of silicon nitride
ceramics for external partners. The Company presently manufactures
silicon nitride powders and components in its FDA registered, ISO
13485:2016 certified, and ASD9100D certified manufacturing
facility.
For more information on SINTX Technologies or its silicon
nitride material platform, please visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA) that are subject to a number of risks
and uncertainties. Risks and uncertainties that may cause such
differences include, among other things: market acceptance of the
rebranding of company products FleX SN; volatility in the price of
SINTX’s common stock; the uncertainties inherent in new product
development, including the cost and time required to commercialize
such product(s); market acceptance of our products once
commercialized; SINTX’s ability to raise funding and other
competitive developments. Readers are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of
the date on which they are made and reflect management’s current
estimates, projections, expectations and beliefs. There can be no
assurance that any of the anticipated results will occur on a
timely basis or at all due to certain risks and uncertainties, a
discussion of which can be found in SINTX’s Risk Factors disclosure
in its Annual Report on Form 10-K, filed with the Securities and
Exchange Commission (SEC) on March 22, 2021, and in SINTX’s other
filings with the SEC. SINTX disclaims any obligation to update any
forward-looking statements. SINTX undertakes no obligation to
publicly revise or update the forward-looking statements to reflect
events or circumstances that arise after the date of this
report.
Business Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
Media Inquiries for SINTX: Amanda Barry
Associate Director, Content and PR The Summit Group
abarry@summitslc.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Mar 2024 to Apr 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Apr 2023 to Apr 2024